CSL Total Liabilities 2017-2024 | CSLLY

CSL total liabilities for the quarter ending June 30, 2024 were $18.621B, a 97.96% increase year-over-year.

  • CSL total liabilities for 2024 were $18.621B, a 1.16% increase from 2023.
  • CSL total liabilities for 2023 were $18.408B, a 33.69% increase from 2022.
  • CSL total liabilities for 2022 were $13.769B, a 40.85% increase from 2021.

CSL Total Liabilities 2017-2024 | CSLLY

  • CSL total liabilities for 2024 were $18.621B, a 1.16% increase from 2023.
  • CSL total liabilities for 2023 were $18.408B, a 33.69% increase from 2022.
  • CSL total liabilities for 2022 were $13.769B, a 40.85% increase from 2021.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$127.1B
Gilead Sciences (GILD)$114.2B
Bristol Myers Squibb (BMY)$112.1B
Regeneron Pharmaceuticals (REGN)$89.7B
GSK (GSK)$74.4B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Biogen (BIIB)$25.4B
BioNTech SE (BNTX)$25.4B
Illumina (ILMN)$24.2B
Moderna (MRNA)$19.9B
BeiGene (BGNE)$19.7B
Incyte (INCY)$15.6B
Genmab (GMAB)$14.8B
Insmed (INSM)$13B
Vaxcyte (PCVX)$13B
BioMarin Pharmaceutical (BMRN)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$12B
Exelixis (EXEL)$10.1B
Exact Sciences (EXAS)$10.1B
QIAGEN (QGEN)$10B
Revolution Medicines (RVMD)$9.9B
Intra-Cellular Therapies (ITCI)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$8.2B
Ascendis Pharma (ASND)$7.8B
Halozyme Therapeutics (HALO)$7.7B